RU2715708C2 - Ингибиторы fgfr4 - Google Patents

Ингибиторы fgfr4 Download PDF

Info

Publication number
RU2715708C2
RU2715708C2 RU2016118981A RU2016118981A RU2715708C2 RU 2715708 C2 RU2715708 C2 RU 2715708C2 RU 2016118981 A RU2016118981 A RU 2016118981A RU 2016118981 A RU2016118981 A RU 2016118981A RU 2715708 C2 RU2715708 C2 RU 2715708C2
Authority
RU
Russia
Prior art keywords
alkyl
mmol
compound
group
dimethoxyphenyl
Prior art date
Application number
RU2016118981A
Other languages
English (en)
Russian (ru)
Other versions
RU2016118981A (ru
RU2016118981A3 (enExample
Inventor
Доминик Рейнолдс
Мин-Хун ХАО
Джон ВАН
Судип ПРАДЖАПАТИ
Такаси САТОХ
Ананд СЕЛВАРАДЖ
Original Assignee
Эйсай Ар Энд Ди Менеджмент Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эйсай Ар Энд Ди Менеджмент Ко., Лтд. filed Critical Эйсай Ар Энд Ди Менеджмент Ко., Лтд.
Publication of RU2016118981A publication Critical patent/RU2016118981A/ru
Publication of RU2016118981A3 publication Critical patent/RU2016118981A3/ru
Application granted granted Critical
Publication of RU2715708C2 publication Critical patent/RU2715708C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/16—Halogenated acetic acids
    • C07C53/18—Halogenated acetic acids containing fluorine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
RU2016118981A 2013-10-18 2014-10-16 Ингибиторы fgfr4 RU2715708C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361892881P 2013-10-18 2013-10-18
US61/892,881 2013-10-18
PCT/US2014/060857 WO2015057938A1 (en) 2013-10-18 2014-10-16 Pyrimidine fgfr4 inhibitors

Publications (3)

Publication Number Publication Date
RU2016118981A RU2016118981A (ru) 2017-11-23
RU2016118981A3 RU2016118981A3 (enExample) 2018-06-25
RU2715708C2 true RU2715708C2 (ru) 2020-03-03

Family

ID=51842899

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016118981A RU2715708C2 (ru) 2013-10-18 2014-10-16 Ингибиторы fgfr4

Country Status (33)

Country Link
US (4) US9434697B2 (enExample)
EP (2) EP3057943B1 (enExample)
JP (2) JP6139788B2 (enExample)
KR (1) KR101826015B1 (enExample)
CN (2) CN105899490B (enExample)
AR (1) AR098048A1 (enExample)
AU (2) AU2014337291B9 (enExample)
BR (1) BR112016008110B1 (enExample)
CA (1) CA2924206C (enExample)
CL (1) CL2016000918A1 (enExample)
CY (1) CY1121129T1 (enExample)
DK (1) DK3057943T3 (enExample)
ES (1) ES2679521T3 (enExample)
HR (1) HRP20181129T1 (enExample)
HU (1) HUE039268T2 (enExample)
IL (1) IL244373B (enExample)
JO (1) JO3515B1 (enExample)
LT (1) LT3057943T (enExample)
MX (1) MX378288B (enExample)
MY (1) MY184733A (enExample)
NZ (1) NZ717559A (enExample)
PE (1) PE20160679A1 (enExample)
PH (1) PH12016500676B1 (enExample)
PL (1) PL3057943T3 (enExample)
PT (1) PT3057943T (enExample)
RS (1) RS57444B1 (enExample)
RU (1) RU2715708C2 (enExample)
SG (1) SG11201602069WA (enExample)
SI (1) SI3057943T1 (enExample)
SM (1) SMT201800379T1 (enExample)
TW (1) TWI597268B (enExample)
UA (1) UA116920C2 (enExample)
WO (2) WO2015057963A1 (enExample)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
SMT201700146T1 (it) 2012-06-13 2017-05-08 Incyte Holdings Corp Composti triciclici sostituiti come inibitori di fgfr
CA2878412A1 (en) 2012-07-11 2014-01-16 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
AR095464A1 (es) 2013-03-15 2015-10-21 Celgene Avilomics Res Inc Compuestos de heteroarilo y usos de los mismos
UA120248C2 (uk) 2013-03-15 2019-11-11 Селджен Кар Ллс Гетероарильні сполуки та їх застосування
MX374558B (es) 2013-03-15 2025-03-06 Sanofi Sa Compuestos de heteroarilo y sus usos.
CA2909207C (en) 2013-04-19 2021-11-02 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
HUE039268T2 (hu) * 2013-10-18 2018-12-28 Eisai R&D Man Co Ltd Pirimidin FGFR4 inhibitorok
EP3060563B1 (en) 2013-10-25 2018-05-02 Novartis AG Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
LT3395814T (lt) 2013-10-25 2022-07-25 Blueprint Medicines Corporation Fibroblastų augimo faktoriaus receptoriaus inhibitoriai
US9695165B2 (en) 2014-01-15 2017-07-04 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
US20180185341A1 (en) 2014-10-03 2018-07-05 Novartis Ag Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
UA121669C2 (uk) 2015-02-20 2020-07-10 Інсайт Корпорейшн Біциклічні гетероцикли як інгібітори fgfr
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9802917B2 (en) 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
WO2016164703A1 (en) * 2015-04-09 2016-10-13 Eisai R & D Management Co., Ltd. Fgfr4 inhibitors
JP6431622B2 (ja) * 2015-04-14 2018-11-28 エーザイ・アール・アンド・ディー・マネジメント株式会社 結晶性ｆｇｆｒ４阻害剤化合物およびその使用
CA2991645A1 (en) 2015-07-20 2017-01-26 Dana-Farber Cancer Institute, Inc. Novel pyrimidines as egfr inhibitors and methods of treating disorders
BR112018001053A2 (pt) 2015-07-20 2018-09-11 Univ Taipei Medical compostos, composição farmacêutica e método para inibir, prevenir ou tratar um câncer em um indivíduo
CN105418441A (zh) * 2015-12-22 2016-03-23 中国工程物理研究院化工材料研究所 2,3-二氯-4-羟基苯胺的制备方法
CN109071521B (zh) * 2016-01-08 2019-10-25 杭州英创医药科技有限公司 作为fgfr抑制剂的杂环化合物
EP3454898B1 (en) * 2016-05-10 2021-11-10 Eisai R&D Management Co., Ltd. Drug combinations for reducing cell viability and/or cell proliferation
TWI669300B (zh) * 2016-05-20 2019-08-21 浙江海正藥業股份有限公司 嘧啶類衍生物、其製備方法、其藥物組合物以及其在醫藥上的用途
CN107400092B (zh) * 2016-05-20 2021-08-24 浙江海正药业股份有限公司 嘧啶类衍生物及其制备方法和其在医药上的用途
CN105884760B (zh) * 2016-06-13 2019-01-04 厦门市蔚嘉化学科技有限公司 一种可比司他中间体的制备方法
JP7190425B2 (ja) * 2016-08-23 2022-12-15 エーザイ・アール・アンド・ディー・マネジメント株式会社 肝細胞癌の治療のための併用療法
WO2018049233A1 (en) 2016-09-08 2018-03-15 Nicolas Stransky Inhibitors of the fibroblast growth factor receptor in combination with cyclin-dependent kinase inhibitors
WO2018055503A1 (en) 2016-09-20 2018-03-29 Novartis Ag Combination comprising a pd-1 antagonist and an fgfr4 inhibitor
US11229643B2 (en) 2016-11-02 2022-01-25 Novartis Ag Combinations of FGFR4 inhibitors and bile acid sequestrants
CA3043948C (en) * 2016-11-17 2021-08-31 Guangdong Zhongsheng Pharmaceutical Co., Ltd Fgfr4 inhibitor and preparation method and use thereof
KR101812266B1 (ko) 2016-11-25 2017-12-27 한국과학기술연구원 4-((2-아크릴아미도페닐)아미노)티에노[3,2-d]피리미딘-7-카복스아미드 유도체 및 그의 약학적 활용
CN108239069B (zh) * 2016-12-26 2021-01-05 南京药捷安康生物科技有限公司 一种用于成纤维细胞生长因子受体的抑制剂及其用途
CN108503593B (zh) * 2017-02-28 2021-04-27 暨南大学 2-氨基嘧啶类化合物及其应用
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
WO2019024876A1 (zh) * 2017-08-04 2019-02-07 上海和誉生物医药科技有限公司 一种具有fgfr4抑制活性的醛基吡啶衍生物、其制备方法和应用
CN109422760B (zh) * 2017-09-01 2022-05-27 南京圣和药物研发有限公司 Fgfr4抑制剂及其应用
CA3074885A1 (en) 2017-09-05 2019-03-14 Bioardis Llc Aromatic derivative, preparation method for same, and medical applications thereof
JP7352569B2 (ja) 2018-01-10 2023-09-28 エーザイ・アール・アンド・ディー・マネジメント株式会社 肝細胞癌の治療のための併用療法
SMT202400507T1 (it) 2018-05-04 2025-01-14 Incyte Corp Forme solide di un inibitore di fgfr e procedimenti per preparare le stesse
SG11202010882XA (en) 2018-05-04 2020-11-27 Incyte Corp Salts of an fgfr inhibitor
WO2019242689A1 (zh) * 2018-06-22 2019-12-26 北京赛特明强医药科技有限公司 一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用
WO2020177067A1 (en) 2019-03-05 2020-09-10 Bioardis Llc Aromatic derivatives, preparation methods, and medical uses thereof
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
CN118930524A (zh) 2019-05-10 2024-11-12 德西费拉制药有限责任公司 苯基氨基嘧啶酰胺自噬抑制剂及其使用方法
CN114072397B (zh) 2019-05-10 2025-03-28 德西费拉制药有限责任公司 杂芳基氨基嘧啶酰胺自噬抑制剂及其使用方法
PE20221083A1 (es) 2019-06-17 2022-07-05 Deciphera Pharmaceuticals Llc Inhibidores de la autofagia de la amida aminopirimidina y sus metodos de uso
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CN112341344B (zh) * 2019-08-09 2021-10-26 上海喀露蓝科技有限公司 一种激酶抑制剂中间体的制备方法
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CA3157361A1 (en) 2019-10-14 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11897891B2 (en) 2019-12-04 2024-02-13 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
WO2021113462A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
CN113087671B (zh) * 2019-12-23 2022-10-21 北京赛特明强医药科技有限公司 一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021231928A1 (en) 2020-05-15 2021-11-18 Eisai R&D Management Co., Ltd. A method for treating cancer with an oral dosage form of an fgfr4 inhibitor
WO2021230886A1 (en) 2020-05-15 2021-11-18 Eisai R&D Management Co., Ltd. A method for treating cancer with an oral dosage form of an fgfr4 inhibitor
CN113943251A (zh) * 2020-07-16 2022-01-18 正大天晴药业集团股份有限公司 双环庚烯基氨基取代的氮杂芳环类化合物及其医药用途
CN116406298A (zh) 2020-10-05 2023-07-07 凯奥目生物科学株式会社 癌治疗用药物
CN114621106A (zh) * 2020-12-11 2022-06-14 重庆医药工业研究院有限责任公司 一种酪氨酸激酶药物中间体的制备方法
CA3215903A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
EP4352060A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CN115490670A (zh) * 2021-06-17 2022-12-20 浙江海正药业股份有限公司 Fgfr4选择性抑制剂的盐及其制备方法和用途
CN115504965A (zh) 2021-06-23 2022-12-23 浙江海正药业股份有限公司 嘧啶类衍生物的晶型及其制备方法
CN114276266B (zh) * 2021-12-30 2024-10-11 兰州康鹏威耳化工有限公司 一种4-氨基-2-氟苯甲酰胺的制备方法
CN114560815A (zh) * 2022-03-04 2022-05-31 北京工业大学 (2-((5-氯-取代苯基氨基嘧啶-2-基)氨基)苯基)氨基甲酸叔丁酯类衍生物
CN116947825B (zh) * 2022-04-14 2025-11-28 浙江海正药业股份有限公司 Fgfr4选择性抑制剂化合物的晶型及其制备方法和用途
CN114835640B (zh) * 2022-05-24 2024-02-13 中国药科大学 成纤维细胞生长因子受体抑制剂、制备方法及应用
EP4509142A1 (en) 2023-08-16 2025-02-19 Ona Therapeutics S.L. Fgfr4 as target in cancer treatment

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2045520C1 (ru) * 1987-03-28 1995-10-10 Циба-Гейги АГ Производные 2-анилино-пиримидина или их соли, проявляющие фунгицидную активность
WO2011071821A1 (en) * 2009-12-07 2011-06-16 Novartis Ag Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea and salts thereof.
WO2014149164A1 (en) * 2013-03-15 2014-09-25 Celgene Avilomics Research, Inc. Mk2 inhibitors and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL139599A0 (en) 1998-05-26 2002-02-10 Warner Lambert Co Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
AU2003285012A1 (en) 2002-10-24 2004-05-13 Sepracor, Inc. Compositions comprising zopiclone derivatives and methods of making and using the same
JP2007500725A (ja) 2003-07-29 2007-01-18 アイアールエム・リミテッド・ライアビリティ・カンパニー プロテインキナーゼ阻害剤としての化合物および組成物
GB0512324D0 (en) * 2005-06-16 2005-07-27 Novartis Ag Organic compounds
WO2006038112A1 (en) 2004-10-01 2006-04-13 Warner-Lambert Company Llc Use of kinase inhibitors to promote neochondrogenesis
BRPI0620408B8 (pt) 2005-12-21 2021-05-25 Novartis Ag derivados de pirimidinil aril uréia sendo inibidores de fgf, seus usos, e preparação farmacêutica
EP1918376A1 (en) 2006-11-03 2008-05-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs
PT2114900T (pt) * 2007-01-31 2019-01-17 Ym Biosciences Australia Pty Compostos à base de tiopirimidina e as suas utilizações
US20090062320A1 (en) 2007-08-28 2009-03-05 Vito Guagnano Method of Treating Disorders Mediated by the Fibroblast Growth Factor Receptor
CA3031835C (en) 2008-06-27 2021-09-07 Celgene Car Llc Heteroaryl compounds and uses thereof
WO2011090738A2 (en) 2009-12-29 2011-07-28 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
IN2012DN05017A (enExample) 2010-01-14 2015-10-02 Univ Yale
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
WO2012136732A1 (en) 2011-04-08 2012-10-11 Ab Science Treatment of multiple myeloma with masitinib
CN102816162B (zh) 2011-06-10 2016-04-27 中国科学院广州生物医药与健康研究院 嘧啶并嘧啶酮类化合物及其药用组合物和应用
CA2862424A1 (en) 2012-01-18 2013-07-25 Genentech, Inc. Methods of using fgf19 modulators
MX349120B (es) 2012-02-28 2017-07-12 Astellas Pharma Inc Compuesto heterociclico aromatico que contiene nitrogeno.
CA2878412A1 (en) 2012-07-11 2014-01-16 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
MX374558B (es) * 2013-03-15 2025-03-06 Sanofi Sa Compuestos de heteroarilo y sus usos.
AU2014287209B2 (en) 2013-07-09 2019-01-24 Dana-Farber Cancer Institute, Inc. Kinase inhibitors for the treatment of disease
TW201605452A (zh) 2013-08-28 2016-02-16 安斯泰來製藥股份有限公司 以嘧啶化合物作爲有效成分之醫藥組成物
HUE039268T2 (hu) * 2013-10-18 2018-12-28 Eisai R&D Man Co Ltd Pirimidin FGFR4 inhibitorok
LT3395814T (lt) 2013-10-25 2022-07-25 Blueprint Medicines Corporation Fibroblastų augimo faktoriaus receptoriaus inhibitoriai
US9695165B2 (en) 2014-01-15 2017-07-04 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
EP3444250A4 (en) 2016-05-20 2019-09-25 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. FGFR4 INHIBITOR, MANUFACTURING METHOD AND APPLICATIONS THEREOF
TWI669300B (zh) 2016-05-20 2019-08-21 浙江海正藥業股份有限公司 嘧啶類衍生物、其製備方法、其藥物組合物以及其在醫藥上的用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2045520C1 (ru) * 1987-03-28 1995-10-10 Циба-Гейги АГ Производные 2-анилино-пиримидина или их соли, проявляющие фунгицидную активность
WO2011071821A1 (en) * 2009-12-07 2011-06-16 Novartis Ag Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea and salts thereof.
WO2014149164A1 (en) * 2013-03-15 2014-09-25 Celgene Avilomics Research, Inc. Mk2 inhibitors and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Vito Guagnano et al., Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{ 6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl} -1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase, Journal of Medicinal Chemistry 2011,v.54, no.20, 7066-7083. *

Also Published As

Publication number Publication date
TW201605802A (zh) 2016-02-16
US20200206222A1 (en) 2020-07-02
IL244373A0 (en) 2016-04-21
AU2014337291A1 (en) 2016-03-17
SI3057943T1 (en) 2018-08-31
CL2016000918A1 (es) 2016-11-11
US9434697B2 (en) 2016-09-06
HUE039268T2 (hu) 2018-12-28
SG11201602069WA (en) 2016-04-28
IL244373B (en) 2018-10-31
CN110354128A (zh) 2019-10-22
AU2014337291B2 (en) 2018-12-13
EP3421457B1 (en) 2021-10-06
NZ717559A (en) 2021-07-30
BR112016008110B1 (pt) 2019-07-02
CN105899490B (zh) 2019-07-23
HK1223091A1 (en) 2017-07-21
ES2679521T3 (es) 2018-08-28
MX378288B (es) 2025-03-10
CY1121129T1 (el) 2019-12-11
RU2016118981A (ru) 2017-11-23
PL3057943T3 (pl) 2018-09-28
CA2924206A1 (en) 2015-04-23
SMT201800379T1 (it) 2018-09-13
EP3057943B1 (en) 2018-04-25
EP3057943A1 (en) 2016-08-24
US10912774B2 (en) 2021-02-09
AU2018271284A1 (en) 2018-12-20
JP2016535000A (ja) 2016-11-10
US10537571B2 (en) 2020-01-21
HRP20181129T1 (hr) 2018-09-21
JO3515B1 (ar) 2020-07-05
JP6139788B2 (ja) 2017-05-31
WO2015057938A1 (en) 2015-04-23
CA2924206C (en) 2022-10-25
AR098048A1 (es) 2016-04-27
RS57444B1 (sr) 2018-09-28
UA116920C2 (uk) 2018-05-25
US9730931B2 (en) 2017-08-15
TWI597268B (zh) 2017-09-01
US20170007601A1 (en) 2017-01-12
WO2015057963A1 (en) 2015-04-23
PE20160679A1 (es) 2016-08-04
LT3057943T (lt) 2018-11-12
EP3421457A1 (en) 2019-01-02
KR101826015B1 (ko) 2018-02-06
DK3057943T3 (en) 2018-07-30
AU2014337291B9 (en) 2020-05-07
RU2016118981A3 (enExample) 2018-06-25
MX2016004933A (es) 2016-12-20
AU2018271284B2 (en) 2020-05-28
US20170360785A1 (en) 2017-12-21
PT3057943T (pt) 2018-07-24
MY184733A (en) 2021-04-20
PH12016500676A1 (en) 2016-05-30
JP2017160233A (ja) 2017-09-14
US20160130237A1 (en) 2016-05-12
KR20160072113A (ko) 2016-06-22
PH12016500676B1 (en) 2022-07-20
CN105899490A (zh) 2016-08-24

Similar Documents

Publication Publication Date Title
RU2715708C2 (ru) Ингибиторы fgfr4
US11498916B2 (en) Crystalline FGFR4 inhibitor compound and uses thereof
US20180057465A1 (en) Inhibitors of Necroptosis
US20180155320A1 (en) 2-oxo-1,2-dihydropyridine-3-carboxamide compounds and their use as inhibitors of pdk1
HK1223091B (en) Pyrimidine fgfr4 inhibitors